US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Hedge fund Citadel takes short position in GSK, FT reports
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...
FDA approves GSK vaccine to combat meningococcal infections
Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...
FiercePharma15h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Citadel takes $384.5 million short position in GSK - FT
Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...
Here’s the dividend forecast for GSK shares through to 2026!
City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...
GSK Class Action News: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Involving GSK PLC
SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...
FierceBiotech3d
GSK plans to move vaccine R&D group from Maryland to the Boston area
After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...
GSK launches $2.5 billion buyback, lifts sales target after stellar Q4
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
FierceBiotech10d
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...